Cargando…
Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non–Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak Trials
Patient-level data from 2 phase III studies in patients with previously untreated, advanced-stage, nonsquamous non–small cell lung cancer (NSCLC) were pooled to examine outcomes with bevacizumab and chemotherapy based on age. METHODS: Data from patients randomized to paclitaxel–carboplatin (PC)+beva...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5016219/ https://www.ncbi.nlm.nih.gov/pubmed/25628268 http://dx.doi.org/10.1097/COC.0000000000000163 |
_version_ | 1782452542945361920 |
---|---|
author | Langer, Corey J. Socinski, Mark A. Patel, Jyoti D. Sandler, Alan B. Schiller, Joan H. Leon, Larry Hazard, Sebastien J. Ramalingam, Suresh S. |
author_facet | Langer, Corey J. Socinski, Mark A. Patel, Jyoti D. Sandler, Alan B. Schiller, Joan H. Leon, Larry Hazard, Sebastien J. Ramalingam, Suresh S. |
author_sort | Langer, Corey J. |
collection | PubMed |
description | Patient-level data from 2 phase III studies in patients with previously untreated, advanced-stage, nonsquamous non–small cell lung cancer (NSCLC) were pooled to examine outcomes with bevacizumab and chemotherapy based on age. METHODS: Data from patients randomized to paclitaxel–carboplatin (PC)+bevacizumab in the Eastern Cooperative Oncology Group 4599 (E4599) and PointBreak studies were pooled and compared with E4599 patients randomized to PC alone. Patients were grouped by age: below 65, 65 to 74, 70 to 74, below 75, and 75 years or above. A multivariable model was used to calculate hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) using time-to-event outcomes. Adverse events (AEs) were assessed by age group in each study. RESULTS: The PC+bevacizumab and PC arms comprised 901 and 444 patients, respectively. PC+bevacizumab was associated with significant increases in overall survival relative to PC in patients below 65 years (hazards ratio [HR], 0.75; 95% confidence interval [CI], 0.62-0.89), 65 to 74 years (HR, 0.80; 95% CI, 0.64-1.00), 70 to 74 years (HR, 0.68; 95% CI, 0.48-0.96), and below 75 years (HR, 0.78; 95% CI, 0.68-0.89) but not in those aged 75 years or above (HR, 1.05; 95% CI, 0.70-1.57). Increased incidence of grade ≥3 AEs was reported with PC+bevacizumab versus PC in patients below 75 years (63% vs. 48%; P<0.05) and 75 years or above (81% vs. 56%; P <0.05) in E4599. CONCLUSIONS: This analysis suggests that the survival benefits associated with PC+bevacizumab extend to patient subgroups below 75 years with advanced-stage NSCLC; no benefit, however, was observed for bevacizumab-eligible patients who were 75 years or above. |
format | Online Article Text |
id | pubmed-5016219 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-50162192016-10-01 Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non–Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak Trials Langer, Corey J. Socinski, Mark A. Patel, Jyoti D. Sandler, Alan B. Schiller, Joan H. Leon, Larry Hazard, Sebastien J. Ramalingam, Suresh S. Am J Clin Oncol Original Articles: Thoracic Patient-level data from 2 phase III studies in patients with previously untreated, advanced-stage, nonsquamous non–small cell lung cancer (NSCLC) were pooled to examine outcomes with bevacizumab and chemotherapy based on age. METHODS: Data from patients randomized to paclitaxel–carboplatin (PC)+bevacizumab in the Eastern Cooperative Oncology Group 4599 (E4599) and PointBreak studies were pooled and compared with E4599 patients randomized to PC alone. Patients were grouped by age: below 65, 65 to 74, 70 to 74, below 75, and 75 years or above. A multivariable model was used to calculate hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) using time-to-event outcomes. Adverse events (AEs) were assessed by age group in each study. RESULTS: The PC+bevacizumab and PC arms comprised 901 and 444 patients, respectively. PC+bevacizumab was associated with significant increases in overall survival relative to PC in patients below 65 years (hazards ratio [HR], 0.75; 95% confidence interval [CI], 0.62-0.89), 65 to 74 years (HR, 0.80; 95% CI, 0.64-1.00), 70 to 74 years (HR, 0.68; 95% CI, 0.48-0.96), and below 75 years (HR, 0.78; 95% CI, 0.68-0.89) but not in those aged 75 years or above (HR, 1.05; 95% CI, 0.70-1.57). Increased incidence of grade ≥3 AEs was reported with PC+bevacizumab versus PC in patients below 75 years (63% vs. 48%; P<0.05) and 75 years or above (81% vs. 56%; P <0.05) in E4599. CONCLUSIONS: This analysis suggests that the survival benefits associated with PC+bevacizumab extend to patient subgroups below 75 years with advanced-stage NSCLC; no benefit, however, was observed for bevacizumab-eligible patients who were 75 years or above. Lippincott Williams & Wilkins 2016-10 2015-01-26 /pmc/articles/PMC5016219/ /pubmed/25628268 http://dx.doi.org/10.1097/COC.0000000000000163 Text en Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially. http://creativecommons.org/licenses/by-nc-nd/4.0/. |
spellingShingle | Original Articles: Thoracic Langer, Corey J. Socinski, Mark A. Patel, Jyoti D. Sandler, Alan B. Schiller, Joan H. Leon, Larry Hazard, Sebastien J. Ramalingam, Suresh S. Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non–Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak Trials |
title | Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non–Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak Trials |
title_full | Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non–Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak Trials |
title_fullStr | Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non–Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak Trials |
title_full_unstemmed | Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non–Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak Trials |
title_short | Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non–Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak Trials |
title_sort | isolating the role of bevacizumab in elderly patients with previously untreated nonsquamous non–small cell lung cancer: secondary analyses of the ecog 4599 and pointbreak trials |
topic | Original Articles: Thoracic |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5016219/ https://www.ncbi.nlm.nih.gov/pubmed/25628268 http://dx.doi.org/10.1097/COC.0000000000000163 |
work_keys_str_mv | AT langercoreyj isolatingtheroleofbevacizumabinelderlypatientswithpreviouslyuntreatednonsquamousnonsmallcelllungcancersecondaryanalysesoftheecog4599andpointbreaktrials AT socinskimarka isolatingtheroleofbevacizumabinelderlypatientswithpreviouslyuntreatednonsquamousnonsmallcelllungcancersecondaryanalysesoftheecog4599andpointbreaktrials AT pateljyotid isolatingtheroleofbevacizumabinelderlypatientswithpreviouslyuntreatednonsquamousnonsmallcelllungcancersecondaryanalysesoftheecog4599andpointbreaktrials AT sandleralanb isolatingtheroleofbevacizumabinelderlypatientswithpreviouslyuntreatednonsquamousnonsmallcelllungcancersecondaryanalysesoftheecog4599andpointbreaktrials AT schillerjoanh isolatingtheroleofbevacizumabinelderlypatientswithpreviouslyuntreatednonsquamousnonsmallcelllungcancersecondaryanalysesoftheecog4599andpointbreaktrials AT leonlarry isolatingtheroleofbevacizumabinelderlypatientswithpreviouslyuntreatednonsquamousnonsmallcelllungcancersecondaryanalysesoftheecog4599andpointbreaktrials AT hazardsebastienj isolatingtheroleofbevacizumabinelderlypatientswithpreviouslyuntreatednonsquamousnonsmallcelllungcancersecondaryanalysesoftheecog4599andpointbreaktrials AT ramalingamsureshs isolatingtheroleofbevacizumabinelderlypatientswithpreviouslyuntreatednonsquamousnonsmallcelllungcancersecondaryanalysesoftheecog4599andpointbreaktrials |